In a 65‑year‑old female with diabetes mellitus, hypertension, chronic kidney disease stage 4, secondary hyperparathyroidism, recent pelvic abscess, presenting with lower‑extremity edema, elevated blood pressure, and anemia while taking dulaglutide (Trulicity), atorvastatin (Lipitor), chlorthalidone (Hygroten), gabapentin (Neurontin), levothyroxine, lisinopril, and ergocalciferol (Vitamin D‑2), how should I manage her volume overload, hypertension, anemia, and secondary hyperparathyroidism?

Management of Volume Overload, Hypertension, Anemia, and Secondary Hyperparathyroidism in CKD Stage 4

Switch chlorthalidone to a loop diuretic (furosemide or torsemide) for volume overload management, optimize blood pressure control to <130/80 mmHg with continued ACE inhibitor therapy, initiate erythropoiesis-stimulating agent (ESA) therapy for anemia, and treat secondary hyperparathyroidism with active vitamin D therapy after correcting 25-hydroxyvitamin D deficiency.

Volume Overload Management

Your patient requires immediate transition from thiazide-like diuretic to loop diuretic therapy. While chlorthalidone 100 mg daily may have been appropriate earlier, at GFR 38 mL/min/1.73 m² (CKD stage 4), thiazide-like diuretics lose efficacy and loop diuretics become necessary 1.

• Start furosemide 40 mg twice daily or torsemide 20 mg once daily as first-line therapy for edema in CKD stage 4 1
• Torsemide offers superior oral bioavailability and longer duration of action compared to furosemide, which may be advantageous given her CKD 1
• Twice-daily dosing of loop diuretics is preferred over once-daily to maintain consistent diuresis throughout the day 1
• Increase the dose until clinically significant diuresis occurs (target weight loss 0.5-1.0 kg daily) or until maximally effective dose is reached 1

Dietary sodium restriction to <2.0 g/day (<90 mmol/day) is essential and will enhance diuretic efficacy 1. The combination of sodium restriction with diuretic therapy is more effective than either intervention alone 1.

If Diuretic Resistance Develops

Should edema persist despite adequate loop diuretic dosing, consider sequential nephron blockade by adding back a thiazide-like diuretic (chlorthalidone 12.5-25 mg daily or metolazone 2.5-5 mg daily) to the loop diuretic 1. This combination provides synergistic diuresis by blocking sodium reabsorption at multiple tubular sites 1.

Monitor closely for:

• Hypokalemia (common with thiazide and loop diuretics) 1
• Volume depletion and hypotension 1
• Worsening renal function (acceptable if creatinine rises <30% and patient remains asymptomatic) 1

Blood Pressure Management

Target blood pressure <130/80 mmHg based on ACC/AHA 2017 guidelines for patients with CKD 1. The SPRINT trial demonstrated cardiovascular benefits with intensive BP control (SBP <120 mmHg) in CKD patients, though the guideline-recommended target is <130/80 mmHg 1.

Continue lisinopril 40 mg daily as your ACE inhibitor backbone therapy 1. ACE inhibitors (or ARBs) are first-line antihypertensive agents in CKD with or without proteinuria 1.

• Do not discontinue the ACE inhibitor if creatinine rises up to 30% from baseline, as this represents acceptable hemodynamic changes 1
• Only stop if kidney function continues to worsen beyond 30% or refractory hyperkalemia develops 1

Additional Antihypertensive Therapy

Once volume status is optimized with loop diuretics, if BP remains >130/80 mmHg:

• Add a long-acting dihydropyridine calcium channel blocker (amlodipine 5-10 mg daily) as second-line therapy 1
• The combination of ACE inhibitor + diuretic + calcium channel blocker is highly effective and well-tolerated 1
• Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) if there is any concern for heart failure, as they have negative inotropic effects 1

Resistant Hypertension Considerations

If BP remains uncontrolled on three agents (ACE inhibitor, loop diuretic, calcium channel blocker):

• Consider adding spironolactone 12.5-25 mg daily for resistant hypertension 1
• However, monitor potassium closely given CKD stage 4 and concurrent ACE inhibitor use 1
• The recent CLICK trial demonstrated that chlorthalidone effectively lowers BP in stage 4 CKD, reducing 24-hour ambulatory systolic BP by 10.5 mmHg more than placebo 2, 3
• If spironolactone causes hyperkalemia, chlorthalidone (in combination with loop diuretic) serves as an alternative for resistant hypertension 2, 3

Anemia Management

Your patient's hemoglobin of 9.4 g/dL requires treatment with erythropoiesis-stimulating agent (ESA) therapy given her symptomatic presentation and CKD stage 4 1, 4.

Initial Evaluation

Before initiating ESA therapy, complete the following assessments 1:

• Iron studies: Check serum ferritin and transferrin saturation (TSAT)
• Target TSAT >20% and ferritin >100 ng/mL before starting ESA 1
• Vitamin B12 and folate levels to exclude other causes of anemia 1
• Reticulocyte count 1

Iron Supplementation

• If TSAT <30% and ferritin <500 ng/mL, initiate intravenous iron therapy (iron sucrose 200 mg weekly for 3-5 weeks or ferric gluconate) 1
• IV iron is more effective than oral iron in CKD patients and should be prioritized 1
• Oral iron (ferrous sulfate 325 mg daily) is less effective but acceptable if IV access is problematic 1

ESA Therapy Initiation

Start darbepoetin alfa 0.45 mcg/kg subcutaneously every 2 weeks or epoetin alfa 50-100 units/kg subcutaneously three times weekly 1, 4.

• Target hemoglobin 10-11.5 g/dL (avoid targeting >11.5 g/dL due to increased cardiovascular risks) 1, 4
• The decision to initiate ESA at Hb <10 g/dL should be individualized, but given her symptoms (lower extremity edema suggesting volume overload, which can worsen with anemia) and Hb 9.4 g/dL, treatment is appropriate 1
• Monitor hemoglobin every 2-4 weeks during dose titration 1

ESA Precautions

• Use ESAs with caution given her diabetes and cardiovascular risk factors 1
• Avoid ESAs if there is active malignancy or history of stroke 1
• If she develops ESA hyporesponsiveness, investigate for iron deficiency, infection, inflammation, or hyperparathyroidism 1

Secondary Hyperparathyroidism Management

Approximately 80% of patients with CKD stage 4 have secondary hyperparathyroidism 5, 6. Your patient requires screening and treatment.

Initial Assessment

• Check intact PTH, serum calcium, phosphorus, 25-hydroxyvitamin D, and alkaline phosphatase 1, 7
• In CKD stage 4, PTH should be maintained in the range of 2-9 times the upper limit of normal (approximately 70-110 pg/mL) per KDIGO guidelines 1

Treatment Algorithm

Step 1: Correct 25-hydroxyvitamin D deficiency first 1, 5

• She is already on ergocalciferol 50,000 units weekly, which is appropriate 1
• Target 25-hydroxyvitamin D level >30 ng/mL 1, 5

Step 2: Initiate active vitamin D therapy 5

• Start paricalcitol 1 mcg daily or calcitriol 0.25 mcg daily once 25-hydroxyvitamin D is repleted 5
• Paricalcitol has minimal impact on serum calcium and phosphorus compared to calcitriol, making it preferable in CKD stage 4 5
• Alternative: doxercalciferol 2.5 mcg three times weekly 5

Step 3: Phosphate management 1

• Restrict dietary phosphate and consider phosphate binders if serum phosphorus is elevated 1
• Calcium-based binders (calcium acetate 667 mg with meals) or non-calcium binders (sevelamer 800 mg three times daily with meals) 1
• Avoid aluminum-containing binders due to toxicity risk 1

Monitoring

• Recheck PTH, calcium, and phosphorus every 3-5 months in CKD stage 4 1
• Adjust active vitamin D dose based on PTH response and calcium/phosphorus levels 5
• If PTH remains elevated despite vitamin D therapy and phosphate control, consider cinacalcet (though it is primarily approved for dialysis patients) 5

Medication Adjustments and Monitoring

Current Medications Requiring Attention

Dulaglutide (Trulicity) 1.5 mg weekly:

• Continue this medication as GLP-1 receptor agonists have demonstrated cardiovascular and renal benefits in type 2 diabetes with CKD 1, 8
• No dose adjustment needed for eGFR 38 mL/min/1.73 m² 9
• Monitor for gastrointestinal side effects (nausea, vomiting) which could worsen volume status 9

Gabapentin 100 mg three times daily:

• Reduce dose to 100-300 mg once daily given CKD stage 4, as gabapentin is renally cleared and accumulates in kidney disease
• Standard dosing in CKD stage 4 (GFR 15-29 mL/min) is 100-300 mg daily

Atorvastatin 40 mg daily:

• Continue without dose adjustment as statins reduce cardiovascular risk in CKD 1

Levothyroxine 25 mcg daily:

• Continue current dose and monitor TSH every 6-12 months

Antibiotics for Pelvic Abscess

Metronidazole 500 mg IV BID and ceftriaxone 2 g IV daily:

• Metronidazole requires no dose adjustment in CKD stage 4
• Ceftriaxone requires no dose adjustment (maximum 2 g daily is appropriate)
• After completing IV therapy (typically 4-6 weeks total for pelvic abscess), transition to oral antibiotics if clinically appropriate
• Monitor for antibiotic-associated diarrhea which could worsen volume status

Key Monitoring Parameters

Weekly during initial management:

• Body weight (target 0.5-1.0 kg loss daily until euvolemic) 1
• Blood pressure (home monitoring 3-4 times weekly as she is already doing) 1
• Symptoms of volume overload or depletion 1

Every 1-3 months in CKD stage 4:

• Serum creatinine, eGFR, electrolytes (sodium, potassium, bicarbonate) 1
• Hemoglobin (every 2-4 weeks if on ESA) 1
• PTH, calcium, phosphorus 1

Every 6-12 months:

• Lipid panel 1
• HbA1c 1
• TSH 1
• 25-hydroxyvitamin D 1

Common Pitfalls to Avoid

• Do not continue chlorthalidone as monotherapy for volume overload in CKD stage 4—thiazides lose efficacy at GFR <30-40 mL/min/1.73 m² 1, 2
• Do not discontinue lisinopril if creatinine rises <30% from baseline 1
• Do not target hemoglobin >11.5 g/dL with ESA therapy due to increased cardiovascular risks 1, 4
• Do not start active vitamin D before correcting 25-hydroxyvitamin D deficiency 5
• Do not use metformin if eGFR falls below 30 mL/min/1.73 m² 1
• Do not overlook gabapentin dose reduction—this commonly causes sedation and falls in CKD patients when not adjusted